CAR T‑Cell Therapy for Pediatric Autoimmune Diseases: New Insights into Lupus, Dermatomyositis, and Systemic Sclerosis

Recent clinical investigations have extended CD19‑directed chimeric antigen receptor (CAR) T‑cell therapy from oncology into the realm of autoimmune disease, reporting outcomes in refractory systemic lupus erythematosus (SLE) and juvenile inflammatory muscle disorders.

CD19 CAR‑T therapy moves beyond cancer

A case series with longitudinal follow‑up demonstrated that CD19 CAR‑T cells can be safely administered to patients with severe autoimmune pathology, establishing a new therapeutic avenue (Müller et al., 2024). A companion review highlighted the mechanistic rationale for targeting CD19‑positive B cells in autoimmunity (De Benedetti et al., 2024).

Promising results in refractory systemic lupus erythematosus

Anti‑CD19 CAR‑T therapy achieved disease control in adults with refractory SLE, showing rapid remission of clinical activity (Mackensen et al., 2022). In a 2024 Lancet report, an adolescent with rapidly progressive lupus nephritis was weaned off haemodialysis after CAR‑T infusion (Krickau et al., 2024). Two pediatric patients with treatment‑refractory SLE also responded to CD19‑CAR‑T, underscoring applicability across age groups (He et al., 2025). Follow‑up imaging confirmed profound depletion of tissue‑resident B cells, indicating deep immunologic remodeling (Tur et al., 2025).

Application to juvenile inflammatory muscle diseases

Autologous CD19‑targeted CAR‑T cells were employed in a child with refractory juvenile dermatomyositis, resulting in clinical improvement (Nicolai et al., 2024). A pediatric case of MDA5‑positive dermatomyositis with rapidly progressive interstitial lung disease also benefited from CD19 CAR‑T therapy (Paris‑Muñoz et al., 2025). These reports build on earlier epidemiologic work documenting the incidence of juvenile dermatomyositis in the United States (Mendez et al., 2003) and recent insights into anti‑MDA5 antibody–driven disease mechanisms (Lu et al., 2024).

Safety and monitoring considerations

Standardized grading for cytokine release syndrome and neurotoxicity provides a framework for managing acute reactions (Lee et al., 2019). Immune‑effector‑cell‑associated hemophagocytic lymphohistiocytosis‑like syndrome has been described in the context of CAR‑T therapy, highlighting the need for vigilance (Hines et al., 2023). Hematotoxicity grading recommendations further guide clinicians in assessing marrow suppression (Rejeski et al., 2023). Long‑term follow‑up of pediatric B‑ALL patients treated with CD19 CAR‑T has documented sustained remission but also identified rare events such as second primary malignancies (Elsallab et al., 2024) and T‑cell malignancy (Lamble et al., 2024). Ongoing pharmacovigilance efforts aim to capture these late effects (Youssef et al., 2026).

Regulatory pathways and manufacturing innovations

The European Union’s advanced therapy medicinal product regulation (2007) provides a legal basis for CAR‑T therapies, while national “hospital exemption” provisions enable locally manufactured products under specific conditions (Ambrosone & Cometa, 2025). Allogeneic CAR‑T cells are emerging as a complementary platform, offering off‑the‑shelf availability (Del Bufalo et al., 2025). Point‑of‑care production of fresh CAR‑T cells for relapsed/refractory B‑cell acute lymphoblastic leukemia demonstrates feasibility of decentralized manufacturing (Del Bufalo et al., 2025). Multi‑site, place‑of‑care manufacturing has already yielded high remission rates in B‑cell malignancies (Maschan et al., 2021), suggesting a scalable model for autoimmune applications.

Implications for pediatric rheumatology

Epidemiologic data reveal that childhood‑onset SLE presents distinct phenotypic patterns compared with adult disease, with variations in organ involvement and severity across age groups (Ambrose et al., 2016; Massias et al., 2020). Classification criteria for SLE and idiopathic inflammatory myopathies facilitate accurate diagnosis in children and adolescents (Aringer et al., 2019; Lundberg et al., 2017). Recent British Society for Rheumatology guidance outlines age‑spanning management strategies for SLE, emphasizing the role of B‑cell–targeted agents such as rituximab and belimumab (Md Yusof et al., 2023). The advent of CD19 CAR‑T adds a potent, potentially curative option for patients who have exhausted conventional immunosuppression.

Frequently Asked Questions

What is CD19 CAR‑T‑cell therapy and why is it being tested for autoimmune diseases?

CD19 CAR‑T‑cell therapy engineers a patient’s T cells to recognize the CD19 protein on B cells, leading to targeted B‑cell elimination. Because pathogenic autoantibody‑producing B cells drive diseases such as SLE and dermatomyositis, researchers have investigated CD19 CAR‑T as a way to reset the immune system (Müller et al., 2024; De Benedetti et al., 2024).

Which autoimmune conditions have shown a response to CD19 CAR‑T in recent studies?

Clinical reports document remission or marked improvement in refractory systemic lupus erythematosus (Mackensen et al., 2022; Krickau et al., 2024; He et al., 2025), juvenile dermatomyositis (Nicolai et al., 2024), and MDA5‑positive dermatomyositis with interstitial lung disease (Paris‑Muñoz et al., 2025).

What safety issues are associated with CD19 CAR‑T treatment for autoimmune patients?

Key risks include cytokine release syndrome, neurotoxicity, hemophagocytic‑like syndromes, and prolonged B‑cell aplasia. Long‑term surveillance has identified rare secondary cancers and potential T‑cell malignancies, prompting recommendations for rigorous pharmacovigilance (Lee et al., 2019; Hines et al., 2023; Elsallab et al., 2024; Lamble et al., 2024; Youssef et al., 2026).

How might the expanding use of CD19 CAR‑T reshape treatment pathways for children with severe autoimmune disease?